Unique IVIDA stem cell bank Spanish, present at the World Congress of blood from umbilical cord held in Boston.
Madrid, January of 2013- IVIDA has been present at the end of September at the World Congress of umbilical cord blood, which has taken place in Boston, USA. The Congress, which coincided with the American Congress for stem cell and regenerative, medicine has tried various topics related to the conservation of blood from umbilical cord for family use.
IVIDA, which was the only Spanish company present at the event, has been able to share knowledge and praxis with powerful private sector in America and Europe, in addition to listening to by major agencies regulatory and research groups, the latest news about the possible use of the umbilical cord for use autologous (own person) or allogeneic blood (between different individuals).
The Conference program has covered all possible areas: current market and future Outlook, models of banks (public, private, mixed), regulation and accreditation of banks, financing of research, applications of the blood of the umbilical cord in areas as different as: ear repair, type 1 diabetes, cell expansion, engineering fabrics, etc. Likewise, has been discussed around the quality control which should be conducted on the banks of umbilical cord and in the improvement of processes with the aim of improving post-transplant implantation rates.
IVIDA is the Bank of cord blood of the IVI group, European leader in reproductive medicine. IVIDA collects, processes, Cryo-preserved and stored stem cells from the blood of Umbilical cord (SCU) for the treatment of various diseases such as lymphomas, leukemias and anemias.
These stem cells can generate red blood cells (for transporting oxygen through the bloodstream), WBC (to defend ourselves against external aggression) and platelets (which promote clotting and prevent hemorrhages).
They also have the ability to regenerate the bone marrow and immune system when it is depressed, either by own bone marrow illness, or by a previous chemotherapy treatment (used as conditioning prior to the patient preparation which will be transplanted with hematopoietic stem cells). ∆l is harmless both for the mother and child. due to the immaturity of this cell type, presents minor compatibility issues and therefore a lower risk of rejection. In addition to current uses, in the future these stem cells could have many more therapeutic applications, which are currently at preclinical stage. In addition, being a treatment with the cells that bind to mother and son, presents no ethical problems.
